Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on June 11, 2019. The report details a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Keith Schmidt to the Board of Directors, effective June 11, 2019. Mr. Schmidt was also appointed to the Audit Committee and the Compensation Committee. He will serve until the 2019 Annual Meeting of Stockholders or until a successor is elected.
Management Commentary and Risks
- Director Background: Mr. Schmidt, age 69, brings over 35 years of healthcare executive experience, including roles as Chief Commercial Officer at Ballantyne Therapeutics and Chelsea Therapeutics International.
- Independence: The Board determined that Mr. Schmidt satisfies the independence requirements of NASDAQ Rule 5605(a)(2) and SEC Rule 10A-3.
- Compensation: Mr. Schmidt is eligible for compensation under the Company's Non-Employee Director Compensation Plan. No related party transactions exist.
- Risks: No specific financial risks or contingencies were disclosed in this filing.
Investor Verification Checklist
- Verify the exact terms of Mr. Schmidt's compensation under the Non-Employee Director Compensation Plan.
- Confirm the date of the 2019 Annual Meeting of Stockholders to determine the end of Mr. Schmidt's initial term.
- Review the attached Exhibit 99.1 (Press Release dated June 12, 2019) for additional context on the appointment.